Discovering the Phase 1 candidate CCT289346/BOS172722 for the treatment of triple negative breast cancer. 


Treating cancer remains a huge scientific challenge despite significant progress in the last decades. Treatment options for many cancer types are very limited and is some cases no effective treatments are available resulting in poor prognosis for these patients. In this seminar, I will briefly summarise why cancer is so difficult to treat. I will then describe a drug discovery project that has been going on at The Institute of Cancer Research. The aim of this project was to discover small molecule inhibitors of the mitotic kinase MPS1 as a new treatment for triple negative breast cancer (TNBC). TNBC is significant fraction of all breast cancers. It is characterised by a significantly worse prognosis than other breast cancers types and remains an area of unmet medical need. I will give an over of the MPS1project from its inception to the discovery of our clinical candidate BOS172722 that is currently undergoing phase I clinical trials. A particular emphasis will be on the medicinal chemistry aspects of the project conducted in my research team. 

Link to the talk will be on our Moodle Page – See you then!